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Hilde RH de Geus1,4*, Gijs Fortrie2, Michiel GH Betjes2, Ron HN van Schaik3 and AB Johan Groeneveld1Abstract
Background: The predictive value of acute kidney injury (AKI) urinary biomarkers may depend on the time interval
following tubular injury, thereby explaining in part the heterogeneous performance of these markers that has been
reported in the literature. We studied the influence of timing on the predictive values of tubular proteins, measured
before the rise of serum creatinine (SCr) in critically ill, non-septic patients.
Methods: Seven hundred adult critically ill patients were prospectively included for urine measurements at four
time-points prior to the rise in serum creatinine (T = 0, -16, -20 and −24 h). Patients with sepsis and or AKI at ICU
entry were excluded. The urinary excretion of the proteins, neutrophil gelatinase-associated lipocalin (NGAL) and
kidney injury molecule-1 (KIM-1), which are up-regulated in the distal and proximal tubules, respectively, were
measured as well as the constitutive cytoplasmatic enzymes, π- and α-glutathione-S-transferase (GST), which are
released by the distal and proximal tubules, respectively.
Results: Five hundred and forty-three subjects were eligible for further analyses; however, 49 developed AKI in the
first 48 h. Both NGAL (P = 0.001 at T = −24 vs. non-AKI patients) and KIM-1 (P < 0.0001 at T = 0 vs. non-AKI patients)
concentrations gradually increased until AKI diagnosis, whereas π- and α-GST peaked at T = −24 before AKI (P = 0.006
and P = 0.002, respectively vs. non-AKI patients) and showed a rapid decline afterwards. The predictive values at T =−24
prior to AKI were modest for π- and α-GST, whereas NGAL sufficiently predicted AKI at T = −24 and its predictive power
improved as the time interval to AKI presentation decreased (area under the receiver operating characteristic curve;
AUC = 0.79, P < 0.0001). KIM-1 was a good discriminator at T = 0 only (AUC = 0.73, P < 0.0001).
Conclusions: NGAL, KIM-1, pi- and alpha-GST displayed unique and mutually incomparable time dependent
characteristics during the development of non-sepsis related AKI. Therefore, the time-relationship between the
biomarker measurements and the injurious event influences the individual test results.
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There is an on-going search for biomarkers for AKI predic-
tion. These biomarkers, may help, in the future, to guide
preventive and therapeutic measures to benefit patients
[1-13]. The AKI-induced up regulation of low molecular
weight proteins, such as neutrophil gelatinase-associated
lipocalin (NGAL) and kidney injury molecule-1 (KIM-1),* Correspondence: h.degeus@erasmusmc.nl
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have been studied in AKI patients and patients who are
at risk for the condition [6-9,11,13-18]. Currently, NGAL,
presumably from distal tubular origins at least in experi-
mental AKI [19], is the most frequently described human
AKI biomarker, although it is not perfect, and NGAL
is considered as a reference standard [3,5,6,8-13,20,21].
Nevertheless, the literature possesses a marked hetero-
geneity in its reported AKI predictive power. The clinical
value of KIM-1, a predominantly ischaemic proximal tubu-
lar injury marker [1,4,5], remains uncertain, with reports
suggesting superiority [1,4] or inferiority [3,5,13] comparedl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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zymes, π- and α-glutathione-S-transferase (GST), are
detectable in the urine when the cell wall integrity of
the distal and the proximal tubules are damaged, respect-
ively [22]. However, the few clinical studies regarding the
AKI predictive value of these enzymatic markers are con-
flicting [2,3,9,23] and the only comparison evaluating
urinary NGAL was limited to a post cardiac surgery study
[9]. Additionally, the available literature reports heteroge-
neous predictive performances for AKI biomarkers in
different patient populations and conditions, such as
adult vs. pediatric patients, sepsis vs. non-sepsis states,
surgical vs. non-surgical conditions, developing vs. estab-
lished AKI and fixed vs. non-fixed intervals between
injury and sampling.
In this study we aimed to evaluate the predictive
performance variation of urinary AKI biomarkers that
precede the rise in serum creatinine (SCr). Additionally, we
sought to study their individual kinetics as a function of
time in non-septic patients, because predictive values and
optimal cut-off levels for AKI markers may differ between
septic and non-septic AKI [24]. In contrast to our previous
study, which included AKI at ICU entry [11], the primary
endpoint for the current study was AKI development
within 48 h following ICU admission. Indeed, AKI predic-
tion is more useful than confirming established AKI; how-
ever, many previous studies grouped together developing
and established AKI, thereby potentially leading to predict-
ive value overestimation [1-6,8-10,12,13,21].
Methods
Setting
This was a prospective single centre cohort study in a
30-bed closed format university hospital intensive care
unit (ICU) in which general surgical, trauma, medical,
neurological and neurosurgical, but not cardiac sur-
gery, patients were treated. All consecutively admitted
adult critically ill patients, between September 1, 2007,
and April 1, 2008, were considered eligible. Exclusion
criteria included the following: patients under 18 years
of age, readmissions during the inclusion period, re-
fusal of informed consent, a history of nephrectomy,
documented chronic kidney disease (CKD) (>stage 3)
or kidney transplantation and a sepsis diagnosis at the
time of ICU entry. Sepsis and CKD were applied as
exclusion criteria to avoid their confounding roles in
biomarker expression. The study was approved by the
Erasmus MC University Medical Centre Institutional
review board (Rotterdam, the Netherlands). Deferred
patient consent was used in combination with written
informed consent that was obtained from the partici-
pants or their health care proxy within 48 h follow-
ing ICU admission. In the consent refusal cases (n = 6,
0.9%), the collected urine specimens were appropriatelydestroyed. This study was a sub-study of a previously re-
ported study [11].
Protocol, sample collection and processing
Demographic data were recorded, including the severity
of illness scores, several renal and outcome parameters
(such as the hospital discharge serum creatinine levels),
the duration of ICU stay and the 28-day and in-hospital
mortality rates. Serum creatinine values were available at
the time of admission and at 6:00 am daily thereafter,
until 72 h after entry. AKI diagnoses were approximated
and calculated during admission and as close as possible
24 and 48 hours after admission. The serum creatinine
levels were measured in the hospital’s clinical chemical
laboratory with a Roche enzymatic kit, (which provided
similar results to a well-regarded reference method) based
on isotope dilution mass spectrometry. Urinary output
and fluid balances were also recorded. At ICU admission
(T = 0), and at T = 4, 8, 24 hrs thereafter, urine samples
were collected using a urine catheter. The samples were
processed in the hospital’s laboratory and the supernatants
were stored at −80°C. NGAL (Triage® immunoassay, Bio-
site Inc. Alere, San Diego, CA, USA), KIM-1, π- GST, and
α-GST (Argutus Medical, Dublin, Ireland) concentrations
were measured using research-based immunoassays. The
detection limits for the urine NGAL assays were 2.6 -
4100 ng/ml. The assays’ coefficient of variation was 13.9%.
The π- GST, α-GST and KIM-1 assay detection limits
were 3.12-100 ng/ml, 6.25-200 ng/ml and 0–10 ng/ml, re-
spectively. These assays average coefficient of variation in
this study were 4%, 3% and 1%, respectively.
Definitions
The baseline serum creatinine levels were defined as the
steady state levels four weeks to six months prior to ICU
admission. If these values were not available, the admis-
sion value was applied as the baseline. The sepsis cri-
teria were a clinically suspected or confirmed infection,
a temperature above 38.5°C or below 36.0°C, tachycardia
(>90 beats/min) and tachypnea (>20/min) or necessity
for mechanical ventilation, and leukocytosis >12 ×109/L
or >10% bands, or leukopenia <4 ×109/L. AKI was defined
using the acute kidney injury network (AKIN) classification
for serum creatinine changes relative to a steady state base-
line value (AKIN 0 = no-AKI, AKIN 1 = serum creatinine
increase >50% or an absolute serum creatinine rise of
0.3 mg/dL (=26.5 μmol/L) compared to baseline, AKIN
2 = serum creatinine increase >100% and AKIN 3 = serum
creatinine increase >200%) without using the urine output
(UP) criteria. To plot the biomarker expression levels that
preceded AKI, the time-points following ICU admission
were recoded as the time-points preceding AKI. AKI
occurred either at T = 24 or T = 48 following ICU ad-
mission. The initial AKI time-point was recoded as T = 0
Table 1 Patient characteristics
Non-AKI Developing AKI P
(N = 432) (N = 49)
Age, years 57(25) 61(25) 0.04
Gender male, n (%) 243(56) 38(77) 0.004
BMI (kg/m2) 24.6(4.8) 25.1(4.4) 0.67
APACHE II 16(9) 23(11) <0.001
SOFA 4(4) 9(6) <0.001
Admission diagnosis, n (%)
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were recoded relative to T = 0 (including T = −48, T = −44,
T = −40, T = −24, T = −20 and T = −16 hrs). Fifty-six pa-
tients had more than one ICU admission; therefore, only
the data from their first admission were used.
Statistical analysis
Patients were grouped according to whether they lacked
AKI or had a developing AKI within the first 48 h of
admission. Most continuous data were distributed non-
normally (Kolmogorov-Smirnov test P < 0.05). We com-
pared developing AKI patients and non-AKI patients
using univariate analyses for continuous variables (Mann–
Whitney U test) and categorical variables (using the χ2 or
Fisher exact test). Two-tailed tests were used throughout.
Receiver operating characteristics curve (ROC) analyses
were used to assess the predictive value of biomarkers
in developing AKI patients. The area under the curve
(AUC), with 95% confidence intervals [95% CI], was
calculated and compared. Statistical analyses were per-
formed with the SPSS statistical software package, ver-
sion 16.0 (SPSS, Chicago, IL, USA) for windows as well
as MedCalc for Windows, version 9.5.0.0 (MedCalc
Software, Mariakerke, Belgium). The data were reported
as numbers (percentages) or as medians (with interquartile
ranges), where appropriate. Means and standard errors
of the mean (SEM), however, were used in the time
course graphs for the sake of clarity. A P ≤ 0.05 was con-
sidered statistically significant, and exact values are pre-
sented throughout.Figure 1 Study cohort flow chart. N: number; AKI: acute kidney
injury; established AKI: AKI at the time of ICU admission and
developing AKI: AKI developing at or 24 hours following admission.Results
Patient characteristics
Seven hundred consecutive ICU admissions were in-
cluded in the study. Six patients refused consent (0.9%),
6 patients had previously undergone a nephrectomy
(0.9%), 56 admissions were counted as readmissions dur-
ing the study period (8%) and 25 patients had chronic
kidney disease (CKD) stage 3 or a kidney transplant
(4%). Of the remaining 607 patients, 64 subjects were di-
agnosed with sepsis; therefore these patients were also
excluded, leaving 543 cases for the final analysis. Out of
the 111 patients with AKI within the first 48 hours of
admission, 62 of these patients (56%) had already met
the AKI criteria at the time of ICU entry, leaving 49
developing AKI subjects (Figure 1). The admission diag-
noses were subdivided into non-cardiac postoperative
(N = 185), respiratory insufficiency (N = 110), subarachnoid
or intracerebral bleeding (N = 99), multi-trauma (N = 42),Medical 100(23) 18(36) 0.11
Surgical 215(49) 20(40)
Neurological 117(27) 11(22)
Renal characteristics
Baseline SCr (mg/dl) 0.74(0.3) 0.85(0.3) 0.002
UP (ml/kg/h) 1.1(0.8) 0.9(0.9) 0.32
FB (l) 1.9(3.0) 4.3(4.4) <0.001
AKIN-stages, n (%)
AKIN-1 34
AKIN-2 11
AKIN-3 4
Patients with CVVH, n (%) 3(6)
Outcome
SCr at hospital discharge (mg/dl) 0.68(0.2) 0.77(0.6) 0.002
ICU days 3(5) 7(11) <0.001
28-day mortality (%) 53(12) 15(30) 0.002
Hospital mortality (%) 59(13) 17(34) 0.001
Abbreviations: AKI: acute kidney injury; BMI: body mass index: APACHE II: Acute
physiology and chronic health evaluation score; SOFA score: sequential organ
failure assessment score; UP: urine production in 24 h after admission per kg
ideal body weight; FB: fluid balance in 24 h; CVVH: continuous veno-venous
haemofiltration; ICU: intensive care unit. Median (IQR) or number of patients
(percentage) where appropriate.
Figure 2 (See legend on next page.)
de Geus et al. BMC Nephrology 2013, 14:273 Page 4 of 7
http://www.biomedcentral.com/1471-2369/14/273
(See figure on previous page.)
Figure 2 Biomarker patterns after ICU admission (A) and preceding AKI (B). Biomarker concentrations are expressed in ng/ml and data
represent the mean (standard error of the mean; SEM). NGAL: Neutrophil gelatinase-associated lipocalin; KIM-1: Kidney injury molecule-1; GST:
glutathione-S-transferase; AKI: acute kidney injury. Mean biomarker concentrations in AKI patients vs. non-AKI patients at each time-point were
compared using the Mann–Whitney U test (A) and the mean biomarker concentrations in AKI patients were compared to the pooled mean value
of all available non-AKI measurements using the Mann–Whitney U test (B). Panel A represents the un-recoded data plotted against the time
following ICU admission. Panel B represents the recoded data prior to the rise in SCr.
Table 2 ROC curves for developing AKI predictions vs.
non-AKI patients
Biomarker Time AUC (95% CI) P
NGAL T = -24 0.66 (0.57-0.75) 0.0005
T = -20 0.66 (0.57-0.75) 0.001
T = -16 0.68 (0.57-0.78) 0.0004
T = 0 0.79 (0.73-0.85) <0.0001
KIM-1 T = 0 0.73 (0.64-0.83) <0.0001
π-GST T = -24 0.65 (0.56-0.75) 0.0006
T = -20 0.64 (0.54-0.73) 0.006
α-GST T = -20 0.65 (0.56-0.75) 0.002
Abbreviations: ROC: receiver operating characteristics curve; AKI: acute kidney
injury; GST: glutathione-s- transferase, KIM-1: kidney injury molecule 1 and
NGAL: neutrophil gelatinase associated lipocalin.
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(N = 28), cardio pulmonary resuscitation (N= 26), haemor-
rhagic shock (N = 20), multi organ failure (N = 2) and lung
transplantation cases (N = 1) with one missing diagnosis.
The developing AKI patients were older, more severely
ill and more often male (Table 1). Furthermore, the de-
veloping AKI patients had higher pre-admission baseline
serum creatinine levels and a higher cumulative fluid
balance within the first 24 h of ICU admission. At hos-
pital discharge, SCr values were higher in patients who
had an AKI episode compared with the non-AKI pa-
tients. Additionally, the 28-day and hospital mortality
rates were higher as well in the AKI patients.
The biomarker patterns following ICU admission
The biomarker levels following ICU admission for the
developing AKI patients and those without AKI are
shown in Figure 2A. This panel represents the not-
recoded data. The upregulated NGAL and KIM-1 protein
concentrations increased over the time following ICU ad-
mission, whereby NGAL increased right from the time of
admission (P < 0.0001); the KIM-1 levels differentiated be-
tween the non-AKI and AKI at the T = 24 hour time point
for the first time (P = 0.008). The KIM-1 concentrations in
the non-AKI patients increased over the time following
ICU admission. The constitutive enzyme concentrations,
π- and α-GST, both decreased but remained higher up
until 8 hours after admission in the AKI compared to the
non-AKI patients (P ≤ 0.048 and P ≤ 0.017 respectively).
The biomarker patterns preceding AKI
Figure 2B shows the pre-AKI biomarker patterns. All
available non-AKI biomarker values were pooled to rep-
resent the non-AKI concentration in the graph repre-
sented at T = −72. The upregulated proteins KIM-1 and
NGAL gradual increased in concentration prior to the
SCr increase. KIM-1, however, was different in the AKI
patients compared with the non-AKI patients right at
the time of AKI presentation (T = 0, P < 0.0001). This
contrasted with NGAL, which displayed a quicker response
with different concentrations in the AKI compared with
the non-AKI patients, starting at 24 hours prior to the AKI
presentation time (P = 0.0005). The constitutive enzyme
concentrations, π- and α-GST, peaked at 24 and 20 hours
prior to the times SCr rose (T = 0), respectively, compared
with the non-AKI patients (P = 0.006 and P = 0.0018). Aftera sudden peak, the biomarker concentrations declined
quickly prior to AKI presentation times.
AKI prediction
Table 2 shows the area under de curves (AUC’s) for the
prediction of developing AKI for each individual biomarker
at the different time points. NGAL displayed the most con-
sistent predictive performance, starting 24 hours prior to
AKI presentation (AUC= 0.66, P = 0.0005) and increased
closer to the AKI endpoint (AUC= 0.79, P < 0.0001). In
contrast, KIM-1 only “predicted” AKI at the same time
when the rise in SCr levels occurred for the first time
(AUC= 0.73 P < 0.0001). However, the π- and α-GST pre-
dictive power was modest (AUC= 0.65 for both) even at
their peak concentrations (24 and 20 hours prior to AKI,
respectively).
Discussion
The present study shows that NGAL, KIM-1, pi- and
alpha-GST show unique and mutually incomparable time
dependent characteristics during the development of non-
sepsis related AKI. The time-relationships between the bio-
marker measurements and the injurious renal hit therefore
influenced the individual predictive test results. The consti-
tutive enzymes displayed a narrow time window of expres-
sion, whereas NGAL outperformed KIM-1 in its early
expression levels prior to an AKI diagnosis.
The NGAL predictive value for (non-septic) AKI in
this study is in accordance with other work [3,5,6,8-13,
20,21,25]. The expression pattern of NGAL prior to the
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creases closer to the AKI presentation time. This latter
observation suggests that the time-to-injury relationship
is important and should be obtained for a correct inter-
pretation of its AKI predictive value. KIM-1’s expression
was less accurate and late (in relation to the time of SCr
increase) compared with NGAL in the current study.
This confirms the work by others who also evaluated
adult critically ill patients [1,3,4,7,9]. Moreover, the pre-
dictive value of KIM-1, which only slowly increased in
the time following renal injury, as our data suggest, is
higher if the AKI has already developed, as in cardiac
surgery, rather than if the AKI develops over the course
of time, as in our study [1,4,5,9]. The rise in KIM-1 over
time even when AKI (defined as a rise in SCr) does not
develop can perhaps be explained by subclinical injury,
because KIM-1 is a transmembrane glycoprotein exclu-
sively present in the epithelial cells that survive after in-
jury and facilitate necrotic cell debris phagocytosis [1,9].
This may look, at first sight, like a clinically irrelevant
observation without direct implications. We believe, how-
ever, that this might imply the loss of renal reserve, which
will most likely become relevant when the kidney suffers
new injurious hits.
π- and α-GST were only modest AKI predictors in this
population with slightly better or similar results com-
pared with those reported in adult cardiac surgery
patients (AUC = 0.54 [95% CI 0.42-0.66]) [9,26]. These
data, however, were similar in another cohort of gen-
eral critically ill patients [25]. In an older study, the
markers were suggested to be superior to other enzymes
AUC = 0.93 [0.74-0.99] and 0.89 [0.69-0.98] respectively
[23]; however, these results were not reproduced in sub-
sequent studies. Several other studies described their
diagnostic performances in established AKI [2,26,27].
These results, however, are incomparable to the present
data for these enzymatic markers, the sampling time in
relation to the injurious hit seems to be especially critical
for their ability to predict a rise in SCr at a later time
point. This might make this category of biomarkers less
well applicable in patients without a circumscribed time
point of renal injury, such as is the case in general ICU
patients. However, due to their sudden urine concentra-
tion changes, their applicability might be more appropri-
ate in a setting of that monitors the renal toxic effects of
drugs and contrast agents in the kidneys.
There are several limitations to the current results.
Despite the large initial number of included patients, the
developing AKI patient subset was relatively small, be-
cause 64% of the AKI patients had AKI at ICU entry and
were thus excluded from the current analysis. The sub-
set of patients with developing septic AKI was even
smaller and did not allow for sufficient data analyses,
although it would have been interesting to study thepossible differences in biomarker expression between
both septic related and non-septic related AKI. Despite
the recognition that serum creatinine is a poor indicator
of renal injury, (based on its varying tubular secretion
levels among other reasons), it is still used in many stud-
ies [3,12,28]. Therefore, the usefulness of potentially
more sensitive markers might be underestimated. We
believe this phenomenon is reflected by our data, which
indicate the presence of subclinical tubular injury in
non-AKI patients (i.e., the increase in KIM-1 levels in
non-AKI patients according to the AKIN classification).
Urinary biomarkers can be used in non-anuric AKI only,
therefore, narrowing their clinical applicability. Contro-
versy exists on whether the correction for urinary cre-
atinine concentrations is necessary for the interpretation
of the results. We believe that normalisation to urine
creatinine concentration poses a unique limitation be-
cause AKI patients are not in a steady state of creatin-
ine turnover. Furthermore, several authors have shown
that this effort does not contribute much to the final
outcomes [1,2,5,6,9,13,23].Conclusions
Our current data suggest that the different biomarker
expression pattrens, such as upregulated proteins and
constitutive enzymes, and the time of sampling with re-
spect to the actual time of cellular injury may partially
explain the previously observed predictive value hetero-
geneity. These factors should be taken into account in
future studies.
Abbreviations
AKI: Acute kidney injury; SCr: Serum creatinine; NGAL: Neutrophil gelatinase
associated lipocalin; KIM-1: Kidney injury molecule-1; GST: Glutathione-S-transferase;
ICU: Intensive care unit; CKD: Chronic kidney disease; AKIN: Acute kidney injury
network; ROC: Receiver operating characteristics curve; AUC: Area under the curve;
CI: Confidence interval; SEM: Standard error of the mean.
Competing interests
Hilde de Geus has received speaker fees from Alere. Alere and Argutus
medical kindly provided the biomarker measurements. The other authors
have nothing to declare.
Authors’ contributions
HG conceived the study, participated in the design, created the database,
performed statistical analyses and drafted the manuscript. GF assisted in
additional data collection. MB participated in the study design and helped
draft the manuscript. RS carried out sample processing and storage. JG
participated in the study design, statistical analyses and the drafting of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank the clinical and laboratory staff of the Erasmus University Medical
Center, Rotterdam, the Netherlands. We thank Wil Mol, our nurse coordinator
for her contribution in patient inclusion and study logistics as well as the
patients and their families for their participation. We thank Gillian Parker and
Brian Noland from Alere (San Diego, CA, USA) for the provided NGAL
measurements. We also thank Joe Keenan and Steven Nolan from Argutus
medical for the provided KIM-1 and π- and α-GST measurements.
de Geus et al. BMC Nephrology 2013, 14:273 Page 7 of 7
http://www.biomedcentral.com/1471-2369/14/273Author details
1Department of Intensive Care, Erasmus University Medical Center,
Rotterdam, the Netherlands. 2Department of Nephrology, Erasmus University
Medical Center, Rotterdam, the Netherlands. 3Department of Clinical
Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands.
4Department of Intensive Care Medicine, Erasmus University Medical Center,
H619 PO box 2040, Rotterdam, CA 3000, The Netherlands.
Received: 26 June 2013 Accepted: 6 November 2013
Published: 9 December 2013References
1. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV: Kidney Injury
Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule
injury. Kidney Int 2002, 62:237–244.
2. Herget-Rosenthal S, Poppen D, Husing J, Marggraf G, Pietruck F, Jakob HG,
Philipp T, Kribben A: Prognostic value of tubular proteinuria and enzymuria in
nonoliguric acute tubular necrosis. Clin Chem 2004, 50:552–558.
3. Coca SG, Yalavarthy R, Concato J, Parikh CR: Biomarkers for the diagnosis
and risk stratification of acute kidney injury: a systematic review. Kidney
Int 2008, 73:1008–1016.
4. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P,
Bonventre JV: Urinary biomarkers in the early diagnosis of acute kidney
injury. Kidney Int 2008, 73:863–869.
5. Vaidya VS, Waikar SS, Ferguson MA, Collings FB, Sunderland K, Gioules C,
Bradwin G, Matsouaka R, Betensky RA, Curhan GC, Bonventre JV: Urinary
biomarkers for sensitive and specific detection of acute kidney injury in
humans. Clin Transl Sci 2008, 1:200–208.
6. Siew ED, Ware LB, Gebretsadik T, Shintani A, Moons KG, Wickersham N,
Bossert F, Ikizler TA: Urine neutrophil gelatinase-associated lipocalin
moderately predicts acute kidney injury in critically ill adults. J Am Soc
Nephrol 2009, 20:1823–1832.
7. Liang XL, Liu SX, Chen YH, Yan LJ, Li H, Xuan HJ, Liang YZ, Shi W:
Combination of urinary kidney injury molecule-1 and interleukin-18 as
early biomarker for the diagnosis and progressive assessment of acute
kidney injury following cardiopulmonary bypass surgery: a prospective
nested case–control study. Biomarkers 2010, 15:332–9.
8. Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR: Neutrophil
gelatinase-associated lipocalin in adult septic patients with and without
acute kidney injury. Intensive Care Med 2010, 36:1333–40.
9. Koyner JL, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhter SA, Raman J,
Jeevanandam V, O’Connor MF, Devarajan P, Bonventre JV, Murray PT:
Urinary biomarkers in the clinical prognosis and early detection of acute
kidney injury. Clin J Am Soc Nephrol 2010, 5:2154–2165.
10. Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H,
D’Amico G, Goldsmith D, Devarajan P, Bellomo R: Plasma and urine
neutrophil gelatinase-associated lipocalin in septic versus non-septic acute
kidney injury in critical illness. Intensive Care Med 2010, 36:452–461.
11. de Geus HR, Bakker J, Lesaffre EM, le Noble JL: Neutrophil gelatinase-associated
lipocalin at ICU admission predicts for acute kidney injury in adult patients.
Am J Respir Crit Care Med 2011, 183:907–14.
12. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G,
Krawczeski CD, Koyner JL, Murray P, Zappitelli M, Goldstein SL, Makris K,
Ronco C, Martensson J, Martling CR, Venge P, Siew E, Ware LB, Ikizler TA,
Mertens PR: The outcome of neutrophil gelatinase-associated lipocalin-
positive subclinical acute kidney injury: a multicenter pooled analysis of
prospective studies. J Am Coll Cardiol 2011, 57:1752–1761.
13. Endre ZH, Pickering JW, Walker RJ, Devarajan P, Edelstein CL, Bonventre JV,
Frampton CM, Bennett MR, Ma Q, Sabbisetti VS, Vaidya VS, Walcher AM,
Shaw GM, Henderson SJ, Nejat M, Schollum JB, George PM: Improved
performance of urinary biomarkers of acute kidney injury in the critically
ill by stratification for injury duration and baseline renal function. Kidney
Int 2011, 79:1119–1130.
14. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H,
MacKinnon RW, Li L, Balakrishnan VS, Pereira BJ, Bonventre JV, Jaber B:
Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury
molecule-1 level are associated with adverse outcomes in acute renal
failure. J Am Soc Nephrol 2007, 18:904–912.
15. Liangos O, Tighiouart H, Perianayagam MC, Kolyada A, Han WK, Wald R,
Bonventre JV, Jaber BL: Comparative analysis of urinary biomarkers forearly detection of acute kidney injury following cardiopulmonary bypass.
Biomarkers 2009, 14:423–431.
16. McIlroy DR, Wagener G, Lee HT: Neutrophil gelatinase-associated lipocalin
and acute kidney injury after cardiac surgery: the effect of baseline renal
function on diagnostic performance. Clin J Am Soc Nephrol 2010, 5:211–219.
17. Metzger J, Kirsch T, Schiffer E, Ulger P, Mentes E, Brand K, Weissinger EM,
Haubitz M, Mischak H, Herget-Rosenthal S: Urinary excretion of twenty
peptides forms an early and accurate diagnostic pattern of acute kidney
injury. Kidney Int 2010, 78:1252–62.
18. Wagener G, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT: A comparison
of urinary neutrophil gelatinase-associated lipocalin in patients undergoing
on- versus Off-pump coronary artery bypass graft surgery. J Cardiothorac Vasc
Anesth 2009, 23:195–9.
19. Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM, Viltard M,
Yu W, Forster CS, Gong G, Liu Y, Kulkarni R, Mori K, Kalandadze A, Ratner AJ,
Devarajan P, Landry DW, D’Agati V, Lin CS, Barasch J: The Ngal reporter
mouse detects the response of the kidney to injury in real time. Nat Med
2011, 17:216–222.
20. Bagshaw SM, Haase M, Haase-Fielitz A, Bennett M, Devarajan P, Bellomo R:
A prospective evaluation of urine microscopy in septic and non-septic
acute kidney injury. Nephrol Dial Transplant 2012, 27:582–8.
21. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A: Accuracy
of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and
prognosis in acute kidney injury: a systematic review and meta-analysis.
Am J Kidney Dis 2009, 54:1012–1024.
22. Heemskerk S, Pickkers P, Bouw MP, Draisma A, van der Hoeven JG, Peters WH,
Smits P, Russel FG, Masereeuw R: Upregulation of renal inducible nitric oxide
synthase during human endotoxemia and sepsis is associated with proximal
tubule injury. Clin J Am Soc Nephrol 2006, 1:853–862.
23. Westhuyzen J, Endre ZH, Reece G, Reith DM, Saltissi D, Morgan TJ:
Measurement of tubular enzymuria facilitates early detection of acute
renal impairment in the intensive care unit. Nephrol Dial Transplant 2003,
18:543–551.
24. de Geus HR, Betjes MG, Schaick R, Groeneveld ABJ: Plasma NGAL similarly
predicts acute kidney injury in sepsis and nonsepsis. Biomark Med 2013,
7:415–421.
25. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, Bihorac A,
Birkhahn R, Cely CM, Chawla LS, Davison DL, Feldkamp T, Forni LG, Gong MN,
Gunnerson KJ, Haase M, Hackett J, Honore PM, Hoste EA, Joannes-Boyau O,
Joannidis M, Kim P, Koyner JL, Laskowitz DT, Lissauer ME, Marx G,
McCullough PA, Mullaney S, Ostermann M, Rimmele T, Shapiro NI, Shaw AD,
Shi J, Sprague AM, Vincent JL, Vinsonneau C, Wagner L, Walker MG,
Wilkerson RG, Zacharowski K, Kellum JA: Discovery and validation of cell cycle
arrest biomarkers in human acute kidney injury. Crit Care 2013, 17:R25.
26. Yavuz I, Asgun FH, Bolcal C, Bingol H, Yokusoglu M, Baysan O, Ozgurtas T,
Demirkilic U, Tatar H: Importance of urinary measurement of glutathione
S-transferase in renal dysfunction patients after on- and off-pump coronary
artery bypass surgery. Thorac Cardiovasc Surg 2009, 57:125–129.
27. Seabra VF, Perianayagam MC, Tighiouart H, Liangos O, dos Santos OF,
Jaber BL: Urinary alpha-GST and pi-GST for prediction of dialysis
requirement or in-hospital death in established acute kidney injury.
Biomarkers 2011, 16:709–717.
28. Eijkenboom JJ, van Eijk LT, Pickkers P, Peters WH, Wetzels JF, van der
Hoeven HG: Small increases in the urinary excretion of glutathione
S-transferase A1 and P1 after cardiac surgery are not associated with
clinically relevant renal injury. Intensive Care Med 2005, 31:664–667.
doi:10.1186/1471-2369-14-273
Cite this article as: de Geus et al.: Time of injury affects urinary
biomarker predictive values for acute kidney injury in critically ill,
non-septic patients. BMC Nephrology 2013 14:273.
